Asymptomatic breast cancer in non-participants of the national screening programme in Norway: A confounding factor in evaluation?

Journal of Medical Screening

Volumn 19, Issue 4, 2012, Pages 177-183

  Hoff, Solveig R ^a,b   Klepp, Olbjørn ^a,b   Hofvind, Solveig ^c,d  

^a Møre and Romsdal Hospital Trust   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c CANCER REGISTRY OF NORWAY   (Norway)

^d OSLO METROPOLITAN UNIVERSITY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALGORITHM; ARTICLE; ASYMPTOMATIC DISEASE; BREAST TUMOR; CARCINOMA IN SITU; EARLY DIAGNOSIS; EPIDEMIOLOGY; FEMALE; HEALTH STATUS INDICATOR; HUMAN; MASS SCREENING; METHODOLOGY; MIDDLE AGED; NORWAY; PAGET NIPPLE DISEASE; PATIENT PARTICIPATION; PROGNOSIS; PSYCHOLOGICAL ASPECT; PUBLIC HEALTH; STATISTICS;

AGED; ALGORITHMS; ASYMPTOMATIC DISEASES; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CONFOUNDING FACTORS (EPIDEMIOLOGY); EARLY DETECTION OF CANCER; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MASS SCREENING; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NORWAY; PATIENT PARTICIPATION; PROGNOSIS;

EID: 84878337974     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1258/jms.2013.012090     Document Type: Article

References (24)

1. Nyström L, Rutqvist LE, Wall S, et al. Breast cancer screening with mammography: Overview of Swedish randomised trials. Lancet 1993;341:973-978 [Erratum, Lancet 1993;342:1372]
2. Chu KC, Smart CR, Tarone RE. Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial J Natl Cancer Inst 1988;80:1125-1132
3. Tabár L, Vitak B, Chen TH, et al. Swedish two-county trial: Impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 2011;260:658-663
4. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50-59 years. CMAJ 1992;147:1477-1488 [Erratum CMAJ 1993;148:718]
5. Vainio H, Bianchini F, eds. IARC handbook of cancer prevention. Vol 7. Breast cancer screening. Lyon, France: IARC Press. 2002
6. Schroën AA, Wobbes T, van der Sluis RF. Interval carcinomas of the breast: A group with intermediate outcome. J Surg Oncol 1996;63:141-4
7. Baré M, Bonfill X, Andreu X; Breast Cancer Screening Programme of Sabadell-Cerdanyola Research Group. Relationship between the method of detection and prognostic factors for breast cancer in a community with a screening programme. J Med Screen 2006;13:183-191
8. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: Analysis of randomized screening trials. J Natl Cancer Inst 2005;97:1195-1203
9. Ernst MF, Voogd AC, Coebergh JW, Roukema JA. Breast carcinoma diagnosis, treatment, and prognosis before and after the introduction of mass mammographic screening. Cancer 2004;100:1337-1344
10. Widmark A, Olsen JB. Mammography activity in Norway. Technical results. Report No. 5. Oslo, Norway: Statens Strålevern. 1995 (in Norwegian)
11. Lynge E, Braaten T, Njor SH, et al. Mammography activity in Norway 1983-2008. Acta Oncol 2011;50:1062-1067
12. Hofvind S, Sanderud A. Bruk av mammografi i Norge i 2005 og 2008. Høgskolen i Oslo, Norway, 2010. ISBN 978-82-579-4735-4(in Norwegian)
13. Hofvind S, Geller B, Vacek PM, Thoresen S, Skaane P. Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program. Eur J Epidemiol 2007;22:447-455
14. Perry N, Broeders MJ, de Wolf C, Törnberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. 4th edn. Luxembourg: Office for Official Publications of the European Communities. 2006
15. Haybittle JL, Blamey RW, Elston CW, et al. A prognostic index in primary breast cancer. Br J Cancer 1982;45:361-366
16. Lee AH, Ellis IO. The Nottingham prognostic index for invasive carcinoma of the breast. Pathol Oncol Res 2008;14:113-115
17. Blamey RW, Ellis IO, Pinder SE, et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 2007;43:1548-1555
18. DEretidá G, Giardina C, Martellotta M, Natale T, Ferrarese F. Prognostic factors in breast cancer: The predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 2001;37:591-596
19. Sundquist M, Thorstenson S, Brudin L, Nordenskjöld B. Applying the Nottingham Prognostic Index to a Swedish breast cancer population. South East Swedish Breast Cancer Study Group. Breast Cancer Res Treat 1999;53:1-8
20. Wishart GC, Greenberg DC, Britton PD, et al. Screen-detected vs symptomatic breast cancer: Is improved survival due to stage migration alone? Br J Cancer 2008;98:1741-1744
21. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010;363:1203-1210
22. Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: Trend analysis of WHO mortality database. BMJ 2011;343:d4411
23. Olsen AH, Lynge E, Njor SH, et al. Breast cancer mortality in Norway after the introduction of mammography screening. Int J Cancer 2013;132:208-214
24. Larsen IK, Småstuen M, Johannessen TB, et al. Data quality at the Cancer Registry of Norway: An overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009;45:1218-1231